Q32 Bio (NASDAQ:QTTB) Coverage Initiated by Analysts at Oppenheimer

Oppenheimer initiated coverage on shares of Q32 Bio (NASDAQ:QTTB) in a research note released on Thursday, Marketbeat reports. The brokerage issued an outperform rating and a $50.00 price objective on the stock.

Separately, Piper Sandler initiated coverage on Q32 Bio in a report on Tuesday, April 2nd. They set an overweight rating and a $45.00 price target for the company.

Q32 Bio Stock Up 21.3 %

QTTB opened at $28.89 on Thursday. Q32 Bio has a 1 year low of $8.24 and a 1 year high of $30.92. The firm has a market cap of $93.31 million, a P/E ratio of -0.82 and a beta of -0.10.

Q32 Bio Company Profile

Homology Medicines Inc is a genetic medicines company. Its platform offers human hematopoietic stem cell derived adeno-associated virus vectors to treat disease-causing mutations through gene correction, insertion and knockout. Homology Medicines Inc is based in BEDFORD MA.